WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H341144
CAS#: 178307-42-1 (HCl)
Description: Revaprazan Hydrochloride is a drug that reduces gastric acid secretion which is used for the treatment of gastritis.
Hodoodo Cat#: H341144
Name: Revaprazan Hydrochloride
CAS#: 178307-42-1 (HCl)
Chemical Formula: C22H24ClFN4
Exact Mass: 398.17
Molecular Weight: 398.910
Elemental Analysis: C, 66.24; H, 6.06; Cl, 8.89; F, 4.76; N, 14.05
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 199463-33-7 (free base) 178307-42-1 (HCl)
Synonym: Revaprazan Hydrochloride; YH 1885; YH-1885; YH1885
IUPAC/Chemical Name: 2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride
InChi Key: MALPZYQJEDBIAK-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H23FN4.ClH/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3;/h4-11,16H,12-13H2,1-3H3,(H,24,25,26);1H
SMILES Code: Cl.CC1N(CCc2ccccc12)c3nc(Nc4ccc(F)cc4)nc(C)c3C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 398.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Park JH, Kim DS, Mustapha O, Yousaf AM, Kim JS, Kim DW, Yong CS, Youn YS, Oh KT, Lim SJ, Kim JO, Choi HG. Comparison of a revaprazan-loaded solid dispersion, solid SNEDDS and inclusion compound: Physicochemical characterisation and pharmacokinetics. Colloids Surf B Biointerfaces. 2018 Feb 1;162:420-426. doi: 10.1016/j.colsurfb.2017.12.017. Epub 2017 Dec 12. PubMed PMID: 29248606.
2: Jo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, Park YS, Kim HJ. A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study. Gut Liver. 2015 Sep 23;9(5):607-14. doi: 10.5009/gnl14135. PubMed PMID: 25473078; PubMed Central PMCID: PMC4562777.
3: Song W, Zhang X, Li S, Xu W. Design, synthesis, and preliminary activity evaluation of novel pyrimidine derivatives as acid pump antagonists. Chem Biol Drug Des. 2015 Mar;85(3):306-14. doi: 10.1111/cbdd.12390. Epub 2014 Sep 8. PubMed PMID: 24995399.
4: Li W, Quan P, Zhang Y, Cheng J, Liu J, Cun D, Xiang R, Fang L. Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions. Int J Pharm. 2014 Jan 2;460(1-2):13-23. doi: 10.1016/j.ijpharm.2013.10.038. Epub 2013 Oct 29. PubMed PMID: 24184036.
5: Park JH, Lee DH, Kim JY, Park SY, Yoon H, Park YS, Kim N, Jeong SH, Kim JW, Lee SH, Hwang JH, Jung HC. Gastroesophageal reflux disease with laryngopharyngeal manifestation in Korea. Hepatogastroenterology. 2012 Nov-Dec;59(120):2527-9. doi: 10.5754/hge10294. PubMed PMID: 23178619.
6: Lim YJ, Phan TM, Dial EJ, Graham DY, Lichtenberger LM. In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine. Digestion. 2012;86(2):171-7. doi: 10.1159/000339882. Epub 2012 Aug 14. PubMed PMID: 22907267; PubMed Central PMCID: PMC3477857.
7: Choi HY, Noh YH, Jin SJ, Kim YH, Kim MJ, Sung H, Jang SB, Lee SJ, Bae KS, Lim HS. Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers. Clin Ther. 2012 Sep;34(9):1999-2010. doi: 10.1016/j.clinthera.2012.07.004. Epub 2012 Aug 1. PubMed PMID: 22858177.
8: Jung JW, Kang HR, Kwon JW, Kim TE, Lee SH, Hong KS, Yu KS, Cho SH. The potential inhibitory effect of revaprazan, an acid pump antagonist, on anticoagulation with warfarin. Tohoku J Exp Med. 2011 Aug;224(4):293-300. PubMed PMID: 21799301.
9: Kim JH, Kim EH, Ock C, Hong H, Kim YJ, Kwon KA, Park DK, Hahm KB. Mitigating endoplasmic reticulum stress with revaprazan ameliorates stress-related mucosal disease. J Gastroenterol Hepatol. 2012 Jan;27(1):120-9. doi: 10.1111/j.1440-1746.2011.06838.x. PubMed PMID: 21722181.
10: Ock CY, Lim YJ, Kim YJ, Chung JW, Kwon KA, Kim JH, Hahm KB. Acid pump antagonist-provoked HSP27 dephosphorylation and accentuation rescues stomach from indomethacin-induced damages. J Dig Dis. 2011 Apr;12(2):71-81. doi: 10.1111/j.1751-2980.2011.00482.x. PubMed PMID: 21401892.
11: Li W, Yang Y, Tian Y, Xu X, Chen Y, Mu L, Zhang Y, Fang L. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int J Pharm. 2011 Apr 15;408(1-2):157-62. doi: 10.1016/j.ijpharm.2011.01.059. Epub 2011 Feb 2. PubMed PMID: 21295124.
12: Oak JH, Chung WC, Jung SH, Choi KH, Kim EJ, Kang BK, Kang BR, Kong SE, Paik CN, Lee KM. [Effect of acid pump antagonist (Revaprazan, Revanex(R)) on result of 13C urea breath test in patients with Helicobacter pylori associated peptic ulcer disease]. Korean J Gastroenterol. 2011 Jan;57(1):8-13. Korean. PubMed PMID: 21258195.
13: Park SY. [Effect of acid pump antagonist (Revaprazan, Revanex(R)) on the result of 13C urea breath test in the patients with Helicobacter pylori associated peptic ulcer disease]. Korean J Gastroenterol. 2011 Jan;57(1):1-2. Korean. PubMed PMID: 21258193.
14: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):183-226. PubMed PMID: 19536362.
15: Bayes M. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73. PubMed PMID: 17440629.
16: Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol. 2004 Jan;44(1):73-82. PubMed PMID: 14681344.
17: Li H, Chung SJ, Kim DC, Kim HS, Lee JW, Shim CK. The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. Drug Metab Dispos. 2001 Jan;29(1):54-9. PubMed PMID: 11124230.
18: Han KS, Kim YG, Yoo JK, Lee JW, Lee MG. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats. Biopharm Drug Dispos. 1998 Nov;19(8):493-500. PubMed PMID: 9840211.
19: Han KS, Kim YG, Lee JW, Lee MG. Blood partition and protein binding of a new reversible proton pump inhibitor, YH1885. Biopharm Drug Dispos. 1998 Sep;19(6):413-5. PubMed PMID: 9737823.
20: Han KS, Choi HC, Yoo JK, Lee JW, Lee MG. Determination of a new proton pump inhibitor, YH1885, in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997 Aug 29;696(2):312-6. PubMed PMID: 9323554.
